• Je něco špatně v tomto záznamu ?

Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study

SN. Christiansen, S. Horskjær Rasmussen, M. Ostergaard, M. Pons, B. Michelsen, K. Pavelka, C. Codreanu, A. Ciurea, B. Glintborg, MJ. Santos, I. Sari, Z. Rotar, B. Gudbjornsson, GJ. Macfarlane, H. Relas, F. Iannone, K. Laas, JK. Wallman, M. van de...

. 2024 ; 10 (3) : . [pub] 20240724

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, pozorovací studie, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc24019686

OBJECTIVES: To compare the treatment effectiveness of secukinumab in radiographic (r) versus non-radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe. METHODS: Prospectively collected data on secukinumab-treated axSpA patients with known radiographic status were pooled from nine countries.Remission rates based on patient-reported outcomes (PROs; Numeric Rating Scale (0-10), for example, pain ≤2/Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≤2 and Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (ID) <1.3 after 6/12/24 months of secukinumab treatment were calculated.Remission and drug retention rates in r-axSpA versus nr-axSpA patients were compared by logistic and Cox regression models (unadjusted/adjusted for age+sex/adjusted for multiple confounders). RESULTS: Overall, 1161 secukinumab-treated patients were included (r-axSpA/nr-axSpA: 922/239). At baseline, r-axSpA patients had longer disease duration and higher C reactive protein, were more often male and HLA-B27 positive and had received fewer prior biological or targeted synthetic disease-modifying antirheumatic drugs compared with nr-axSpA patients, whereas PROs were largely similar.During follow-up, crude PRO remission rates were significantly higher in r-axSpA compared with nr-axSpA patients (6 months: pain≤2: 40%/28%, OR=1.7; BASDAI≤2: 37%/25%, OR=1.8), as were drug retention rates (24 months: 66%/58%, HR 0.73 (ref: r-axSpA)). Proportions of patients achieving ASDAS ID were low for both groups, particularly nr-axSpA (6 months: 11%/8%).However, when adjusting for age+sex, these differences diminished, and after adjusting for multiple confounders, no significant between-group differences remained for either remission or drug retention rates. CONCLUSION: Crude remission/drug retention rates in European secukinumab-treated patients were higher in r-axSpA compared with nr-axSpA patients. In adjusted analyses, secukinumab effectiveness was similar in both groups, suggesting that observed differences were related to factors other than radiographic status.

Aberdeen Centre for Arthritis and Musculoskeletal Health University of Aberdeen Aberdeen UK

Amsterdam Rheumatology and Immunology Center Amsterdam Netherlands

Amsterdam UMC Department of Rheumatology and Clinical Immunology and Department of Experimental Immunology Amsterdam Institute for Infection and Immunity University of Amsterdam Amsterdam Netherlands

Center for Rheumatic Diseases University of Medicine and Pharmacy Carol Davila Bucharest Bucuresti Romania

Center for treatment of Rheumatic and Musculoskeletal Diseases Diakonhjemmet Hospital Oslo Norway

Centre for Rheumatology Research Landspitali National University Hospital of Iceland Reykjavik Iceland

Clinical Epidemiology Division Department of Medicine Solna Karolinska Institute Stockholm Sweden

Comprehensive Health Research Centre NOVA Medical School Universidade NOVA de Lisboa Lisboa Portugal

Copenhagen Center for Arthritis Research Center for Rheumatology and Spine Diseases Centre for Head and Orthopedics Rigshospitalet Glostrup Glostrup Denmark

Department for Rheumatology Landspitali National University Hospital of Iceland Reykjavik Iceland

Department of Clinical Medicine Aarhus University Aarhus Denmark

Department of Clinical Medicine University of Copenhagen Copenhagen Denmark

Department of Clinical Sciences Lund Lund University Lund Sweden

Department of Medicine Helsinki University and Helsinki University Hospital Helsinki Finland

Department of Rheumatology Aarhus University Hospital Aarhus Denmark

Department of Rheumatology Bakircay Universitesi Izmir Turkey

Department of Rheumatology East Tallinn Central Hospital Tallinn Estonia

Department of Rheumatology Geneva University Hospitals Geneve Switzerland

Department of Rheumatology Hospital Garcia de Orta EPE Almada Portugal

Department of Rheumatology Hospital General Universitario Gregorio Marañón Madrid Spain

Department of Rheumatology Skåne University Hospital Lund Lund Sweden

Department of Rheumatology University Hospital Zurich Zurich Switzerland

Department of Rheumatology University Medical Centre Ljubljana Ljubljana Slovenia

Division of Rheumatology Dokuz Eylul Universitesi Tip Fakultesi Izmir Turkey

Faculdade de Medicina da Universidade de Lisboa Universidade de Lisboa Instituto de Medicina Molecular Lisboa Portugal

Faculty of Medicine Complutense University of Madrid Madrid Spain

Faculty of Medicine University of Iceland Reykjavik Iceland

Faculty of Medicine University of Ljubljana Ljubljana Slovenia

Faculty of Medicine University of Oslo Oslo Norway

Inflammation Center Rheumatology Helsinki University Central Hospital Helsinki Finland

Institute of Rheumatology and Department of Rheumatology 1st Faculty of Medicine Charles University Praha Czech Republic

National Institute for Health Development Tallinn Estonia

Public Health Section Inland Norway University of Applied Sciences Elverum Norway

Research Unit Sørlandet Sykehus HF Kristiansand Norway

Research Unit Spanish Society of Rheumatology Madrid Spain

Rheumatology Allergology and Clinical Immunology University of Rome Tor Vergata Roma Italy

Rheumatology Department Centro Hospitalar do Baixo Vouga EPE Aveiro Portugal

Rheumatology Radboud University Medical Center Nijmegen Netherlands

Rheumatology Unit DiMePRe J University of Bari Bari Italy

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019686
003      
CZ-PrNML
005      
20241024110651.0
007      
ta
008      
241015s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/rmdopen-2024-004166 $2 doi
035    __
$a (PubMed)39053949
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Christiansen, Sara Nysom $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet Glostrup, Glostrup, Denmark sara.nysom.christiansen@regionh.dk $1 https://orcid.org/0000000250639932
245    10
$a Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study / $c SN. Christiansen, S. Horskjær Rasmussen, M. Ostergaard, M. Pons, B. Michelsen, K. Pavelka, C. Codreanu, A. Ciurea, B. Glintborg, MJ. Santos, I. Sari, Z. Rotar, B. Gudbjornsson, GJ. Macfarlane, H. Relas, F. Iannone, K. Laas, JK. Wallman, M. van de Sande, SA. Provan, I. Castrejon, J. Zavada, C. Mogosan, MJ. Nissen, AG. Loft, A. Barcelos, Y. Erez, KP. Pirkmajer, G. Grondal, GT. Jones, AM. Hokkanen, MS. Chimenti, S. Vorobjov, D. Di Giuseppe, TK. Kvien, L. Otero-Varela, I. van der Horst-Bruinsma, ML. Hetland, LM. Ørnbjerg
520    9_
$a OBJECTIVES: To compare the treatment effectiveness of secukinumab in radiographic (r) versus non-radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe. METHODS: Prospectively collected data on secukinumab-treated axSpA patients with known radiographic status were pooled from nine countries.Remission rates based on patient-reported outcomes (PROs; Numeric Rating Scale (0-10), for example, pain ≤2/Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≤2 and Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (ID) <1.3 after 6/12/24 months of secukinumab treatment were calculated.Remission and drug retention rates in r-axSpA versus nr-axSpA patients were compared by logistic and Cox regression models (unadjusted/adjusted for age+sex/adjusted for multiple confounders). RESULTS: Overall, 1161 secukinumab-treated patients were included (r-axSpA/nr-axSpA: 922/239). At baseline, r-axSpA patients had longer disease duration and higher C reactive protein, were more often male and HLA-B27 positive and had received fewer prior biological or targeted synthetic disease-modifying antirheumatic drugs compared with nr-axSpA patients, whereas PROs were largely similar.During follow-up, crude PRO remission rates were significantly higher in r-axSpA compared with nr-axSpA patients (6 months: pain≤2: 40%/28%, OR=1.7; BASDAI≤2: 37%/25%, OR=1.8), as were drug retention rates (24 months: 66%/58%, HR 0.73 (ref: r-axSpA)). Proportions of patients achieving ASDAS ID were low for both groups, particularly nr-axSpA (6 months: 11%/8%).However, when adjusting for age+sex, these differences diminished, and after adjusting for multiple confounders, no significant between-group differences remained for either remission or drug retention rates. CONCLUSION: Crude remission/drug retention rates in European secukinumab-treated patients were higher in r-axSpA compared with nr-axSpA patients. In adjusted analyses, secukinumab effectiveness was similar in both groups, suggesting that observed differences were related to factors other than radiographic status.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    12
$a humanizované monoklonální protilátky $x terapeutické užití $7 D061067
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a dospělí $7 D000328
650    _2
$a výsledek terapie $7 D016896
650    _2
$a lidé středního věku $7 D008875
650    12
$a axiální spondyloartritida $x farmakoterapie $x etiologie $7 D000089183
650    _2
$a antirevmatika $x terapeutické užití $7 D018501
650    _2
$a prospektivní studie $7 D011446
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a hodnocení výsledků péče pacientem $7 D000071066
650    _2
$a rentgendiagnostika $7 D011859
650    _2
$a indukce remise $7 D012074
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Horskjær Rasmussen, Simon $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet Glostrup, Glostrup, Denmark
700    1_
$a Ostergaard, Mikkel $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet Glostrup, Glostrup, Denmark $u Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
700    1_
$a Pons, Marion $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet Glostrup, Glostrup, Denmark
700    1_
$a Michelsen, Brigitte $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet Glostrup, Glostrup, Denmark $u Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway $u Research Unit, Sørlandet Sykehus HF, Kristiansand, Norway $1 https://orcid.org/0000000301032840
700    1_
$a Pavelka, Karel $u Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic
700    1_
$a Codreanu, Catalin $u Center for Rheumatic Diseases, University of Medicine and Pharmacy Carol Davila Bucharest, Bucuresti, Romania
700    1_
$a Ciurea, Adrian $u Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland $1 https://orcid.org/0000000278707132
700    1_
$a Glintborg, Bente $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet Glostrup, Glostrup, Denmark $u Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark $1 https://orcid.org/0000000289318482
700    1_
$a Santos, Maria Jose $u Department of Rheumatology, Hospital Garcia de Orta EPE, Almada, Portugal $u Faculdade de Medicina da Universidade de Lisboa, Universidade de Lisboa Instituto de Medicina Molecular, Lisboa, Portugal $1 https://orcid.org/0000000279461365
700    1_
$a Sari, Ismail $u Division of Rheumatology, Dokuz Eylul Universitesi Tip Fakultesi, Izmir, Turkey
700    1_
$a Rotar, Ziga $u Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia $u Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia $1 https://orcid.org/0000000293239189
700    1_
$a Gudbjornsson, Bjorn $u Centre for Rheumatology Research, Landspitali National University Hospital of Iceland, Reykjavik, Iceland $u Faculty of Medicine, University of Iceland, Reykjavik, Iceland $1 https://orcid.org/0000000346316505
700    1_
$a Macfarlane, Gary J $u Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, UK $1 https://orcid.org/0000000323223314
700    1_
$a Relas, Heikki $u Inflammation Center, Rheumatology, Helsinki University Central Hospital, Helsinki, Finland
700    1_
$a Iannone, Florenzo $u Rheumatology Unit, DiMePRe-J, University of Bari, Bari, Italy $1 https://orcid.org/0000000304745344
700    1_
$a Laas, Karin $u Department of Rheumatology, East Tallinn Central Hospital, Tallinn, Estonia
700    1_
$a Wallman, Johan K $u Department of Clinical Sciences Lund, Lund University, Lund, Sweden $u Department of Rheumatology, Skåne University Hospital Lund, Lund, Sweden
700    1_
$a van de Sande, Marleen $u Amsterdam UMC, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Institute for Infection & Immunity, University of Amsterdam, Amsterdam, Netherlands $u Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands
700    1_
$a Provan, Sella Aarrestad $u Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway $u Public Health Section, Inland Norway University of Applied Sciences, Elverum, Norway $1 https://orcid.org/000000015442902X
700    1_
$a Castrejon, Isabel $u Department of Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain $u Faculty of Medicine, Complutense University of Madrid, Madrid, Spain
700    1_
$a Zavada, Jakub $u Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic
700    1_
$a Mogosan, Corina $u Center for Rheumatic Diseases, University of Medicine and Pharmacy Carol Davila Bucharest, Bucuresti, Romania
700    1_
$a Nissen, Michael J $u Department of Rheumatology, Geneva University Hospitals, Geneve, Switzerland $1 https://orcid.org/0000000263261764
700    1_
$a Loft, Anne Gitte $u Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark $u Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
700    1_
$a Barcelos, Anabela $u Rheumatology Department, Centro Hospitalar do Baixo Vouga EPE, Aveiro, Portugal $u Comprehensive Health Research Centre, NOVA Medical School, Universidade NOVA de Lisboa, Lisboa, Portugal
700    1_
$a Erez, Yesim $u Department of Rheumatology, Bakircay Universitesi, Izmir, Turkey
700    1_
$a Pirkmajer, Katja Perdan $u Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia $u Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
700    1_
$a Grondal, Gerdur $u Faculty of Medicine, University of Iceland, Reykjavik, Iceland $u Department for Rheumatology, Landspitali National University Hospital of Iceland, Reykjavik, Iceland
700    1_
$a Jones, Gareth T $u Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, UK $1 https://orcid.org/0000000300167591
700    1_
$a Hokkanen, Anna-Mari $u Department of Medicine, Helsinki University and Helsinki University Hospital, Helsinki, Finland
700    1_
$a Chimenti, Maria Sole $u Rheumatology, Allergology and Clinical Immunology, University of Rome Tor Vergata, Roma, Italy $1 https://orcid.org/0000000213431729
700    1_
$a Vorobjov, Sigrid $u National Institute for Health Development, Tallinn, Estonia
700    1_
$a Di Giuseppe, Daniela $u Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden
700    1_
$a Kvien, Tore K $u Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway $u Faculty of Medicine, University of Oslo, Oslo, Norway $1 https://orcid.org/0000000284413093
700    1_
$a Otero-Varela, Lucia $u Research Unit, Spanish Society of Rheumatology, Madrid, Spain
700    1_
$a van der Horst-Bruinsma, Irene $u Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands $1 https://orcid.org/0000000280869915
700    1_
$a Hetland, Merete Lund $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet Glostrup, Glostrup, Denmark $u Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark $1 https://orcid.org/0000000342296818
700    1_
$a Ørnbjerg, Lykke Midtbøll $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet Glostrup, Glostrup, Denmark $1 https://orcid.org/0000000278326831
773    0_
$w MED00188812 $t RMD open $x 2056-5933 $g Roč. 10, č. 3 (2024)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39053949 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024110645 $b ABA008
999    __
$a ok $b bmc $g 2202113 $s 1231659
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 10 $c 3 $e 20240724 $i 2056-5933 $m RMD open $n RMD Open $x MED00188812
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Možnosti archivace